Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo da Influência da Insuflação Intraperitoneal de CO2 por Laparoscopia na Evolução a Curto Prazo de Prematuros com Enterocolite Necrotizante Ulcerativa (NECO2)

4 de novembro de 2026 atualizado por: Assistance Publique - Hôpitaux de Paris

Estudo da Influência da Insuflação Intraperitoneal de Dióxido de Carbono (CO2) por Laparoscopia na Evolução a Curto Prazo de Prematuros com Enterocolite Necrotizante Ulcerativa

Ulcerative-necrotizing enterocolitis (ECUN) is an infectious and inflammatory disease of the digestive tract, which can lead to intestinal necrosis or perforation.

This severe pathology of the newborn , often premature, requires urgent medical and surgical treatment in 25 to 50% of cases. The morbidity is high, both digestive and neurological. ECUN can lead to complications at short-term (death, intestinal stenosis) and at long-term (neuro-cognitive disorders). The challenge of preserving the neurological development is a major issue. It involves control of inflammation. This inflammation causes neurological lesions and is responsible for a disorder of the long-term neurocognitive development.

At Robert-Debré and Trousseau, the management of newborns with ECUN is focused on the control of this inflammation. A laparoscopy is performed first. The carbon dioxide (CO2) insufflated into the abdomen during a laparoscopy is thought to have an anti-inflammatory effect according to several experimental and clinical studies. A preliminary retrospective study at Robert-Debré showed a decrease in postoperative inflammation (decrease in C reactive protein at Day2 and Day 7 post-op) as well as a decrease in morbimortality (decrease in the rate of stoma and reoperation) in children who had a laparoscopic first operation compared to those who had a laparotomy alone. However, in many hospitals, laparotomy alone is currently the only surgical option.

This preliminary study may demonstrate that laparoscopy decreases early morbidity and mortality in children with ECUN through reduced inflammation, as reflected by postoperative C reactive protein.

Visão geral do estudo

Descrição detalhada

NECO2 is a pilot trial, evaluating the intermediate effectiveness to short/medium term of laparoscopy on the inflammatory reaction of premature newborns with complicated ECUN, requiring surgical treatment.

This is a multicenter randomized controlled trial in single blind, in two parallel arms, in ratio 1:1, of superiority.

This trial compares laparoscopy plus laparotomy versus laparotomy alone.

Children will be randomized into 2 groups:

  • Laparoscopy + laparotomy group
  • Laparotomy group

The main objective is to evaluate the inflammatory response Day 2 postoperative in preterm infants with ECUN who have undergone surgery.

The main criterion is the evolution of the blood C reactive protein level between Day 0 and Day 2 postoperatively.

The secondary objectives are:To evaluate in premature babies with ECUN who have had a surgical intervention (laparoscopy + laparotomy or laparotomy alone):

A.The postoperative biological inflammatory response at Day 7 B.Post-operative biological inflammatory response from Day 0 to Day 7 C.Post-operative mortality D.Post-operative bowel morbidity E.Post-operative re-intervention rate F.Length of hospital stay G.Post-operative neurological morbidity, medium term (corrected term 41 SA)

  • To evaluate the tolerance of laparoscopy :

H.Intraoperative cardiorespiratory I.Loco-regional lesions linked to the insertion of the trocar

Secondary endpoints:

A. C reactive protein blood level at Day 7 B. Blood levels of Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha at Day 1, Day 2, Day 4, Day 7 C. Postoperative death from any cause D. Stoma rate, duration of parenteral nutrition, duration of hemodynamic support, duration of invasive ventilation (High frequency oscillatory ventilation/Synchronized Intermittent Mandatory Ventilation), Post-ECUN intestinal stenosis rate E. Re-intervention (laparotomy) and cause (post-ECUN stenosis, stoma closure) F. Length of hospital stay until return home G. Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at the corrected term of 41 weeks of amenorrhea, H. Oxygen saturation (SaO2), hypercapnia (pCO2) blood pressure (BP), cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively I. Intraoperative clinical monitoring: exploration of adjacent organs. Post-operative clinical monitoring: digestive signs monitoring of wounds until discharge.

Group 1: laparotomy only Group 2: laparotomy and laparoscopy

Tipo de estudo

Intervencional

Inscrição (Estimado)

54

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Paris, França, 75012
        • Recrutamento
        • Hôpital Armand Trousseau Service de Chirurgie Pédiatrique et Néonatale
        • Contato:
      • Paris, França
        • Recrutamento
        • Hôpital Robert Debré Service de Chirurgie Pédiatrique
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Premature newborn (term of birth: <37 weeks of amenorrhea)
  • Diagnosis of ECUN by the surgeon (distension abdominal +/- rectal bleeding +/- green gastric residue, increased biological inflammatory syndrome, + pneumatosis on abdominal radiography)
  • Hospitalized and complicated ECUN: presenting either a pneumoperitoneum on abdominal X-ray or a absence of clinical and biological improvement after 48 hours of maximum well-conducted medical treatment (IV antibiotic therapy and digestive rest).
  • Hospitalized in the 2 participating centers
  • Of which the 2 holders of parental authority have been informed and have signed the consent form
  • Having social security coverage (social security or CMU)

Exclusion Criteria:

  • Instability contraindicating movement to the operating room or contraindicating CO2 insufflation
  • Diagnosis of isolated perforation of the small intestine (radiography:

pneumoperitoneum without pneumatosis)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Laparotomy

Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion

Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion

Experimental: Laparotomy and laparoscopy

Exploratory and therapeutic laparotomy if necessary preceded by laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.

Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion

laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
C reactive protein blood level
Prazo: between Day 0 and Day 2 post surgery

C reactive protein blood level

between Day 0 and Day 2 post surgery

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Postoperative biological inflammatory reaction
Prazo: Day 7 post surgery

C reactive protein blood level

Day 7 post surgery
Specific post-operative biological inflammatory reaction
Prazo: Day1, day 2, day 4 and day 7 post surgery

Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha blood level

Day1, day 2, day 4 and day 7 post surgery
Postoperative mortality
Prazo: up to 3 months

Death due to any postoperative cause

up to 3 months
Postoperative intestinal morbidity: stoma rate
Prazo: up to 3 months

Stoma rate

up to 3 months
Postoperative intestinal morbidity: Duration of parenteral nutrition
Prazo: up to 3 months

Duration of parenteral nutrition

up to 3 months
Postoperative intestinal morbidity: Duration of hemodynamic support
Prazo: up to 3 months

Duration of hemodynamic support

up to 3 months
Postoperative intestinal morbidity: Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation)
Prazo: up to 3 months

Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation)

up to 3 months
Postoperative intestinal morbidity: Rate of intestinal stenosis post-ECUN
Prazo: up to 3 months

Rate of intestinal stenosis post-ECUN

up to 3 months
Postoperative reoperation rate
Prazo: up to 3 months

Reoperation (laparotomy) and cause (post ECUN stenosis, stoma closure)

up to 3 months
Length of hospitalization
Prazo: up to 3 months

Duration of hospitalization until return home

up to 3 months
Medium-term postoperative neurological morbidity
Prazo: up to 3 months

Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at term corrected for 41 weeks of amenorrhea

up to 3 months
Oxygen saturation (SaO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Prazo: During Surgery

Oxygen saturation (SaO2)

During Surgery
Hypercapnia (pCO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Prazo: During Surgery

hypercapnia (pCO2)

During Surgery
Blood pressure (BP) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Prazo: During Surgery

blood pressure (systolic and diastolic)

During Surgery
Cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Prazo: During Surgery

cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively

During Surgery
Presence of loco-regional lesions related to the insertion of the trocar (Tolerance of laparoscopy)
Prazo: up to 3 months

Presence of loco-regional lesions related to the insertion of the trocar

up to 3 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

22 de fevereiro de 2024

Conclusão Primária (Real)

22 de junho de 2025

Conclusão do estudo (Estimado)

22 de setembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

24 de abril de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de maio de 2023

Primeira postagem (Real)

31 de maio de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

4 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever